NLRP3 and myelodysplastic syndrome: Inhibiting pyroptosis such as neutralizing S100A9, inhibiting NLRP3 and eliminating Caspase-1 have been shown to improve hematopoietic failure in MDS, providing new therapeutic prospects in MDS (65).